Development of innovative medicines and vaccines to address major public health challenges and improve population health.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Novartis France
B
Research and development of innovative medicines to improve and extend people's lives.
Ceva Santé Animale
A
Development and provision of innovative health solutions for all animals, including vaccines, treatments, and support services.
Initiatives identified among leaders
Engagement en faveur de la responsabilité sociétale
“Ceva Santé Animale s'engage en faveur de la respon...” - Ceva Santé AnimaleMise en place d'un processus de divulgation de vulnérabilités
“Takeda met en place un processus de divulgation de...” - TakedaPréservation de la biodiversité
“Ceva Santé Animale s'engage à préserver la biodive...” - Ceva Santé Animale62% of similar organizations communicate on CSR issues
+4049 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports